MX2010007699A - Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina. - Google Patents

Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.

Info

Publication number
MX2010007699A
MX2010007699A MX2010007699A MX2010007699A MX2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
colorectal carcinoma
imidazo
colon diseases
Prior art date
Application number
MX2010007699A
Other languages
English (en)
Spanish (es)
Inventor
Istvan Szelenyi
Joachim Maus
Ursula Petzold
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of MX2010007699A publication Critical patent/MX2010007699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2010007699A 2008-01-15 2008-12-23 Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina. MX2010007699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
MX2010007699A true MX2010007699A (es) 2010-08-04

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007699A MX2010007699A (es) 2008-01-15 2008-12-23 Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.

Country Status (15)

Country Link
US (1) US8008319B2 (enExample)
EP (1) EP2237780A1 (enExample)
JP (1) JP2011509956A (enExample)
CN (1) CN101909624A (enExample)
AU (1) AU2008347400B2 (enExample)
BR (1) BRPI0822002A2 (enExample)
CA (1) CA2708559C (enExample)
EA (1) EA018579B1 (enExample)
GE (1) GEP20125605B (enExample)
IL (1) IL205819A (enExample)
MX (1) MX2010007699A (enExample)
NZ (1) NZ586161A (enExample)
UA (1) UA101339C2 (enExample)
WO (1) WO2009089900A1 (enExample)
ZA (1) ZA201003906B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
DK4001311T3 (da) 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
FI3641771T3 (fi) 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
RU2006121646A (ru) * 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
CA2708559C (en) 2015-10-06
AU2008347400A1 (en) 2009-07-23
US20090182005A1 (en) 2009-07-16
IL205819A0 (en) 2010-11-30
IL205819A (en) 2013-02-28
CN101909624A (zh) 2010-12-08
EA018579B1 (ru) 2013-09-30
UA101339C2 (ru) 2013-03-25
CA2708559A1 (en) 2009-07-23
EA201001164A1 (ru) 2010-12-30
AU2008347400B2 (en) 2014-12-11
US8008319B2 (en) 2011-08-30
WO2009089900A1 (en) 2009-07-23
NZ586161A (en) 2012-05-25
ZA201003906B (en) 2011-03-30
BRPI0822002A2 (pt) 2015-10-13
EP2237780A1 (en) 2010-10-13
JP2011509956A (ja) 2011-03-31
GEP20125605B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
UA101339C2 (ru) Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных
EP4140487A8 (en) Combination therapy for treating cancer
WO2012143416A3 (en) 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives
ZA201200705B (en) Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
TN2013000237A1 (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
PH12014500379A1 (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
NZ607060A (en) Substituted imidazoquinoline derivatives as kinase inhibitors
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
MX362939B (es) Derivados de (aza-)isoquinolinona.
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
IN2014MN02049A (enExample)
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MY172308A (en) Bicyclic pyrazinone derivatives
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
WO2009087091A3 (en) Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy
MX2014007976A (es) Derivados de imidazopiridina novedosos como un inhibidor de tirosina cinasa.
EP3345597A3 (en) Pkc delta inhibitors for use as therapeutics
WO2011094260A3 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
JP2006504721A5 (enExample)
CA2862718A1 (en) Triazolopyridine derivatives as a tyrosine kinase inhibitor

Legal Events

Date Code Title Description
FG Grant or registration